» Articles » PMID: 14764897

The Role of Shc and Insulin-like Growth Factor 1 Receptor in Mediating the Translocation of Estrogen Receptor Alpha to the Plasma Membrane

Overview
Specialty Science
Date 2004 Feb 7
PMID 14764897
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Our previous studies demonstrated that 17beta-estradiol (E2) rapidly induces the interaction of estrogen receptor alpha (ERalpha) with the adapter protein Shc, the translocation of ERalpha to the cell membrane, and the formation of dynamic membrane structures in MCF-7 breast cancer cells. The present study examined how E2 causes ERalpha to translocate to the region of the plasma membrane and focused on mechanisms whereby Shc and the insulin-like growth factor-1 receptor (IGF-1R) mediate this process. Shc physically interacts with IGF-1R in the plasma membrane, and E2 activates IGF-1R. We reasoned that ERalpha, when bound to Shc, would be directed to the region of the plasma membrane by the same processes, causing membrane translocation of Shc. We confirmed that E2 rapidly induced IGF-1R phosphorylation and demonstrated that E2 induced formation of a ternary protein complex among Shc, ERalpha, and IGF-1R. Knock down of Shc with a specific small inhibitory RNA decreased the association of ERalpha with IGF-1R by 87%, suggesting that Shc is a crucial molecule in the formation of this ternary complex. Confocal microscopy studies provided further confirmation of the functional roles of Shc and the IGF-1R in the translocation of ERalpha to the region of the membrane. Down-regulation of Shc, ERalpha, or IGF-1R with specific small inhibitory RNAs all blocked E2-induced mitogen-activated protein kinase phosphorylation. Together, our results demonstrate that Shc and IGF-1R serve as key elements in the translocation of ERalpha to the cell membrane and in the facilitation of ERalpha-mediated rapid E2 action.

Citing Articles

DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care.

Suba Z Cancers (Basel). 2024; 16(8).

PMID: 38672654 PMC: 11049279. DOI: 10.3390/cancers16081573.


Comparative study of dexamethasone premedication regimens with docetaxel chemotherapy in early HER-2 positive breast cancer: A safety net hospital experience.

Hager A, Kondle S, Agarwal A, Chintapenta M, Horadam R, Sadeghi N J Oncol Pharm Pract. 2024; 31(2):236-244.

PMID: 38425269 PMC: 11898369. DOI: 10.1177/10781552241232692.


A plasma membrane-associated form of the androgen receptor enhances nuclear androgen signaling in osteoblasts and prostate cancer cells.

Kalyanaraman H, Casteel D, Pal China S, Zhuang S, Boss G, Pilz R Sci Signal. 2024; 17(821):eadi7861.

PMID: 38289986 PMC: 10916501. DOI: 10.1126/scisignal.adi7861.


The female syndecan-4 heart has smaller cardiomyocytes, augmented insulin/pSer473-Akt/pSer9-GSK-3β signaling, and lowered SCOP, pThr308-Akt/Akt and GLUT4 levels.

Stole T, Lunde M, Shen X, Martinsen M, Lunde P, Li J Front Cell Dev Biol. 2022; 10:908126.

PMID: 36092718 PMC: 9452846. DOI: 10.3389/fcell.2022.908126.


miR-489 Confines Uncontrolled Estrogen Signaling through a Negative Feedback Mechanism and Regulates Tamoxifen Resistance in Breast Cancer.

Soni M, Saatci O, Gupta G, Patel Y, Raja M, Li J Int J Mol Sci. 2022; 23(15).

PMID: 35897675 PMC: 9331933. DOI: 10.3390/ijms23158086.


References
1.
Watson C, CAMPBELL C, Gametchu B . Membrane oestrogen receptors on rat pituitary tumour cells: immuno-identification and responses to oestradiol and xenoestrogens. Exp Physiol. 1999; 84(6):1013-22. PMC: 1931420. DOI: 10.1111/j.1469-445x.1999.01903.x. View

2.
Jensen E, Jordan V . The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003; 9(6):1980-9. View

3.
Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C . Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem. 2000; 275(24):18447-53. DOI: 10.1074/jbc.M910345199. View

4.
Adams T, Epa V, Garrett T, Ward C . Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000; 57(7):1050-93. PMC: 11146944. DOI: 10.1007/PL00000744. View

5.
Yager J . Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr. 2000; (27):67-73. DOI: 10.1093/oxfordjournals.jncimonographs.a024245. View